Full Text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Three new (13) and 25 known compounds were isolated from the crude extract of Cassia abbreviata. The chemical structures of new compounds were established by extensive spectroscopic analyses including 1D and 2D NMR and HRESIMS. Cassiabrevone (1) is the first heterodimer of guibourtinidol and planchol A. Compound 2 was a new chalcane, while 3 was a new naphthalene. Cassiabrevone (1), guibourtinidol-(4α→8)-epiafzelechin (4), taxifolin (8), oleanolic acid (17), piceatannol (22), and palmitic acid (28), exhibited potent anti-HIV-1 activity with IC50 values of 11.89 µM, 15.39 µM, 49.04 µM, 7.95 µM, 3.58 µM, and 15.97 µM, respectively.

Details

Title
Chemical Constituents of Cassia abbreviata and Their Anti-HIV-1 Activity
Author
Yang, Xianwen 1   VIAFID ORCID Logo  ; He, Zhihui 2 ; Zheng, Yue 3 ; Wang, Ning 4 ; Mulinge, Martin 5   VIAFID ORCID Logo  ; Schmit, Jean-Claude 6 ; Steinmetz, André 4 ; Seguin-Devaux, Carole 7 

 Laboratory of Cellular and Molecular Oncology, Luxembourg Institute of Health, L-1445 Luxembourg, Luxembourg; [email protected] (X.Y.); [email protected] (Y.Z.); [email protected] (N.W.); [email protected] (A.S.); Key Laboratory of Marine Biogenetic Resources, Third Institute of Oceanography, Ministry of Natural Sources, 184 Daxue Road, Xiamen 361005, China; [email protected] 
 Key Laboratory of Marine Biogenetic Resources, Third Institute of Oceanography, Ministry of Natural Sources, 184 Daxue Road, Xiamen 361005, China; [email protected] 
 Laboratory of Cellular and Molecular Oncology, Luxembourg Institute of Health, L-1445 Luxembourg, Luxembourg; [email protected] (X.Y.); [email protected] (Y.Z.); [email protected] (N.W.); [email protected] (A.S.); Department of Infection and Immunity, Luxembourg Institute of Health, L-4354 Esch-sur-Alzette, Luxembourg; [email protected] (M.M.); [email protected] (J.-C.S.) 
 Laboratory of Cellular and Molecular Oncology, Luxembourg Institute of Health, L-1445 Luxembourg, Luxembourg; [email protected] (X.Y.); [email protected] (Y.Z.); [email protected] (N.W.); [email protected] (A.S.) 
 Department of Infection and Immunity, Luxembourg Institute of Health, L-4354 Esch-sur-Alzette, Luxembourg; [email protected] (M.M.); [email protected] (J.-C.S.); Department of Biochemistry, School of Medicine, University of Nairobi, Nairobi P.O. Box 30197-00100, Kenya 
 Department of Infection and Immunity, Luxembourg Institute of Health, L-4354 Esch-sur-Alzette, Luxembourg; [email protected] (M.M.); [email protected] (J.-C.S.); Service National of Infectious Diseases, Centre Hospitalier de Luxembourg, L-1210 Luxembourg, Luxembourg 
 Department of Infection and Immunity, Luxembourg Institute of Health, L-4354 Esch-sur-Alzette, Luxembourg; [email protected] (M.M.); [email protected] (J.-C.S.) 
First page
2455
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
14203049
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2530150753
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.